NASDAQ:ONTX - Onconova Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.9066 -0.47 (-10.74 %) (As of 11/19/2018 12:23 PM ET)Previous Close$4.38Today's Range$3.9066 - $4.3152-Week Range$3.53 - $39.97Volume13,255 shsAverage Volume86,154 shsMarket Capitalization$24.85 millionP/E Ratio-0.10Dividend YieldN/ABeta1.14 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania. Receive ONTX News and Ratings via Email Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONTX Previous Symbol CUSIPN/A Webwww.onconova.com Phone267-759-3680 Debt Debt-to-Equity RatioN/A Current Ratio2.82 Quick Ratio2.82 Price-To-Earnings Trailing P/E Ratio-0.10 Forward P/E Ratio-0.76 P/E GrowthN/A Sales & Book Value Annual Sales$790,000.00 Price / Sales28.04 Cash FlowN/A Price / CashN/A Book Value($15.11) per share Price / Book-0.26 Profitability EPS (Most Recent Fiscal Year)($40.16) Net Income$-24,090,000.00 Net Margins-1,610.44% Return on Equity-965.58% Return on Assets-130.46% Miscellaneous Employees25 Outstanding Shares5,670,000Market Cap$24.85 million OptionableNot Optionable Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions What is Onconova Therapeutics' stock symbol? Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX." When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work? Onconova Therapeutics shares reverse split before market open on Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split. How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics Inc (NASDAQ:ONTX) issued its quarterly earnings data on Tuesday, November, 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.16. The biopharmaceutical company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $1.87 million. Onconova Therapeutics had a negative net margin of 1,610.44% and a negative return on equity of 965.58%. View Onconova Therapeutics' Earnings History. When is Onconova Therapeutics' next earnings date? Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Onconova Therapeutics. What price target have analysts set for ONTX? 2 Wall Street analysts have issued 12-month price objectives for Onconova Therapeutics' shares. Their predictions range from $16.00 to $25.00. On average, they anticipate Onconova Therapeutics' share price to reach $20.50 in the next twelve months. This suggests a possible upside of 424.8% from the stock's current price. View Analyst Price Targets for Onconova Therapeutics. What is the consensus analysts' recommendation for Onconova Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Onconova Therapeutics. What are Wall Street analysts saying about Onconova Therapeutics stock? Here are some recent quotes from research analysts about Onconova Therapeutics stock: 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (11/17/2018) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are adjusting our price target to $25 from $3, accounting for the 1:15 reverse split and the following factors: (1) adjustment to base year; (2) adjustment to fully diluted share count; and (3) adjusting our projected launch years for IV rigosertib in high-risk MDS from 2020 to 2021, and 2021 to 2022 for the U.S. and ex-U.S. markets, respectively. Our clinical NPV model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (9/27/2018) 3. Maxim Group analysts commented, "Onconova reported 2Q18 with a net loss of $4.3M and ended the period with $29.5M in cash, runway into 2H19." (8/14/2018) Has Onconova Therapeutics been receiving favorable news coverage? News headlines about ONTX stock have trended very positive on Monday, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Onconova Therapeutics earned a daily sentiment score of 3.1 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Onconova Therapeutics' key competitors? Some companies that are related to Onconova Therapeutics include Tetraphase Pharmaceuticals (TTPH), Cumberland Pharmaceuticals (CPIX), CTI BioPharma (CTIC), Synergy Pharmaceuticals (SGYP), Chiasma (CHMA), Provention Bio (PRVB), Zynerba Pharmaceuticals (ZYNE), Evofem Biosciences (EVFM), BioXcel Therapeutics (BTAI), BELLUS Health (BLUSF), Axsome Therapeutics (AXSM), Pharmaxis (PXSLY), Entasis Therapeutics (ETTX), Iterum Therapeutics (ITRM) and Checkpoint Therapeutics (CKPT). Who are Onconova Therapeutics' key executives? Onconova Therapeutics' management team includes the folowing people: Dr. Ramesh Kumar, Co-Founder, CEO & Director (Age 62)Dr. Steven M. Fruchtman, Chief Medical Officer & Pres (Age 67)Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 74)Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 55)Mr. Mark Patrick Guerin, Chief Financial Officer (Age 49) Who are Onconova Therapeutics' major shareholders? Onconova Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Tyndall Capital Partners L P (14.40%), EcoR1 Capital LLC (8.82%), Point72 Asset Management L.P. (4.27%), Kepos Capital LP (3.53%) and Renaissance Technologies LLC (0.99%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, E Premkumar Reddy, Henry S Bienen, Mark Patrick Guerin, Michael B Hoffman and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics. Which major investors are selling Onconova Therapeutics stock? ONTX stock was sold by a variety of institutional investors in the last quarter, including Tyndall Capital Partners L P, EcoR1 Capital LLC, Point72 Asset Management L.P., Kepos Capital LP and Renaissance Technologies LLC. View Insider Buying and Selling for Onconova Therapeutics. How do I buy shares of Onconova Therapeutics? Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Onconova Therapeutics' stock price today? One share of ONTX stock can currently be purchased for approximately $3.9066. How big of a company is Onconova Therapeutics? Onconova Therapeutics has a market capitalization of $24.85 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-24,090,000.00 in net income (profit) each year or ($40.16) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe. What is Onconova Therapeutics' official website? The official website for Onconova Therapeutics is http://www.onconova.com. How can I contact Onconova Therapeutics? Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected] MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 195 (Vote Outperform)Underperform Votes: 176 (Vote Underperform)Total Votes: 371MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/19/2018 by MarketBeat.com StaffFeatured Article: Why does a company issue an IPO?